Gufic Biosciences Share Price
Sector: Biotechnology & Drugs
351.00 -1.25 (-0.35%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
347.05
Today’s High
364.95
52 Week Low
285.00
52 Week High
501.10
349.00 -2.65 (-0.75%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
347.00
Today’s High
354.00
52 Week Low
298.80
52 Week High
504.25
Key Metrics
- Market Cap (In Cr) 3519.75
- Beta 0.85
- Div. Yield (%) 0.03
- P/B 5.82
- TTM P/E 48.39
- Sector P/E 22.43
- D/E 0.01
- Open Price 364.95
- Prev Close 352.25
Gufic Biosciences Analysis
Price Analysis
-
1 Week-1.86%
-
3 Months3.82%
-
6 Month-21.48%
-
YTD-23.31%
-
1 Year0.34%
Risk Meter
- 40% Low risk
- 40% Moderate risk
- 40% Balanced Risk
- 40% High risk
- 40% Extreme risk
Gufic Biosciences News
Stocks to buy & sell: Raja Venkatraman recommends three stocks for 13 January
3 min read . 13 Jan 2025Gufic Biosciences share price rises over 4% to hit 52-week high; here's why
1 min read . 19 Jun 2023Gufic Biosciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 819.81
- Selling/ General/ Admin Expenses Total
- 127.05
- Depreciation/ Amortization
- 21.06
- Other Operating Expenses Total
- 183.36
- Total Operating Expense
- 706.18
- Operating Income
- 113.63
- Net Income Before Taxes
- 94.14
- Net Income
- 69.65
- Diluted Normalized EPS
- 6.95
- Period
- 2025
- Total Assets
- 1169.36
- Total Liabilities
- 568.29
- Total Equity
- 601.08
- Tangible Book Valueper Share Common Eq
- 59.31
- Period
- 2025
- Cashfrom Operating Activities
- 122.57
- Cashfrom Investing Activities
- -70.78
- Cashfrom Financing Activities
- -37.2
- Net Changein Cash
- 14.59
- Period
- 2024
- Total Revenue
- 806.67
- Selling/ General/ Admin Expenses Total
- 220.3
- Depreciation/ Amortization
- 17.02
- Other Operating Expenses Total
- 5.41
- Total Operating Expense
- 675.51
- Operating Income
- 131.15
- Net Income Before Taxes
- 115.67
- Net Income
- 86.14
- Diluted Normalized EPS
- 8.92
- Period
- 2024
- Total Assets
- 1092.54
- Total Liabilities
- 559.98
- Total Equity
- 532.56
- Tangible Book Valueper Share Common Eq
- 52.55
- Period
- 2024
- Cashfrom Operating Activities
- -7.46
- Cashfrom Investing Activities
- -102.39
- Cashfrom Financing Activities
- 82.38
- Net Changein Cash
- -27.46
- Period
- 2023
- Total Revenue
- 690.62
- Selling/ General/ Admin Expenses Total
- 178.99
- Depreciation/ Amortization
- 22.28
- Other Operating Expenses Total
- 4.6
- Total Operating Expense
- 575.29
- Operating Income
- 115.33
- Net Income Before Taxes
- 106.72
- Net Income
- 79.7
- Diluted Normalized EPS
- 8.22
- Period
- 2023
- Total Assets
- 861.16
- Total Liabilities
- 513.35
- Total Equity
- 347.81
- Tangible Book Valueper Share Common Eq
- 35.81
- Period
- 2023
- Cashfrom Operating Activities
- -26.59
- Cashfrom Investing Activities
- -190.73
- Cashfrom Financing Activities
- 234.31
- Net Changein Cash
- 16.99
- Period
- 2022
- Total Revenue
- 779.16
- Selling/ General/ Admin Expenses Total
- 169.97
- Depreciation/ Amortization
- 17.13
- Other Operating Expenses Total
- 17.44
- Total Operating Expense
- 650.57
- Operating Income
- 128.58
- Net Income Before Taxes
- 126.84
- Net Income
- 95.84
- Diluted Normalized EPS
- 9.88
- Period
- 2022
- Total Assets
- 521.4
- Total Liabilities
- 252.28
- Total Equity
- 269.12
- Tangible Book Valueper Share Common Eq
- 27.7
- Period
- 2022
- Cashfrom Operating Activities
- 106.24
- Cashfrom Investing Activities
- -94.59
- Cashfrom Financing Activities
- -6.24
- Net Changein Cash
- 5.41
- Period
- 2021
- Total Revenue
- 487.7
- Selling/ General/ Admin Expenses Total
- 117.16
- Depreciation/ Amortization
- 16.29
- Other Operating Expenses Total
- 12.29
- Total Operating Expense
- 420.07
- Operating Income
- 67.63
- Net Income Before Taxes
- 57.71
- Net Income
- 44.23
- Diluted Normalized EPS
- 4.56
- Period
- 2021
- Total Assets
- 392.06
- Total Liabilities
- 218.62
- Total Equity
- 173.44
- Tangible Book Valueper Share Common Eq
- 17.84
- Period
- 2021
- Cashfrom Operating Activities
- 89.06
- Cashfrom Investing Activities
- -8.51
- Cashfrom Financing Activities
- -78.62
- Net Changein Cash
- 1.94
- Period
- 2020
- Total Revenue
- 378.84
- Selling/ General/ Admin Expenses Total
- 117.04
- Depreciation/ Amortization
- 13.86
- Other Operating Expenses Total
- 9.19
- Total Operating Expense
- 340.3
- Operating Income
- 38.54
- Net Income Before Taxes
- 30.13
- Net Income
- 22.69
- Diluted Normalized EPS
- 2.34
- Period
- 2020
- Total Assets
- 407.52
- Total Liabilities
- 278.2
- Total Equity
- 129.32
- Tangible Book Valueper Share Common Eq
- 13.28
- Period
- 2020
- Cashfrom Operating Activities
- 47.1
- Cashfrom Investing Activities
- -42.53
- Cashfrom Financing Activities
- -4.21
- Net Changein Cash
- 0.36
- Period
- 2019
- Total Revenue
- 350.77
- Selling/ General/ Admin Expenses Total
- 93.38
- Depreciation/ Amortization
- 4.64
- Other Operating Expenses Total
- 5.42
- Total Operating Expense
- 309.43
- Operating Income
- 41.34
- Net Income Before Taxes
- 35.35
- Net Income
- 21.94
- Diluted Normalized EPS
- 2.82
- Period
- 2019
- Total Assets
- 279.54
- Total Liabilities
- 204.19
- Total Equity
- 75.35
- Tangible Book Valueper Share Common Eq
- 9.63
- Period
- 2019
- Cashfrom Operating Activities
- 5.21
- Cashfrom Investing Activities
- -12.99
- Cashfrom Financing Activities
- 7.71
- Net Changein Cash
- -0.08
- Period
- 2025-03-31
- Total Revenue
- 205.02
- Selling/ General/ Admin Expenses Total
- 35.57
- Depreciation/ Amortization
- 7.84
- Other Operating Expenses Total
- 53.4
- Total Operating Expense
- 186.49
- Operating Income
- 18.53
- Net Income Before Taxes
- 10.52
- Net Income
- 7.72
- Diluted Normalized EPS
- 0.77
- Period
- 2025-03-31
- Total Assets
- 1169.36
- Total Liabilities
- 568.29
- Total Equity
- 601.08
- Tangible Book Valueper Share Common Eq
- 59.31
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 122.57
- Cashfrom Investing Activities
- -70.78
- Cashfrom Financing Activities
- -37.2
- Net Changein Cash
- 14.59
- Period
- 2024-12-31
- Total Revenue
- 207.79
- Selling/ General/ Admin Expenses Total
- 33.96
- Depreciation/ Amortization
- 4.62
- Other Operating Expenses Total
- 45.75
- Total Operating Expense
- 178.49
- Operating Income
- 29.31
- Net Income Before Taxes
- 26.26
- Net Income
- 19.31
- Diluted Normalized EPS
- 1.93
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 204.18
- Selling/ General/ Admin Expenses Total
- 28.47
- Depreciation/ Amortization
- 4.3
- Other Operating Expenses Total
- 40.96
- Total Operating Expense
- 169.86
- Operating Income
- 34.32
- Net Income Before Taxes
- 29.25
- Net Income
- 21.77
- Diluted Normalized EPS
- 2.17
- Period
- 2024-09-30
- Total Assets
- 1104.67
- Total Liabilities
- 530.49
- Total Equity
- 574.18
- Tangible Book Valueper Share Common Eq
- 56.63
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 89.41
- Cashfrom Investing Activities
- -37.02
- Cashfrom Financing Activities
- -47.78
- Net Changein Cash
- 4.6
- Period
- 2024-06-30
- Total Revenue
- 202.81
- Selling/ General/ Admin Expenses Total
- 29.05
- Depreciation/ Amortization
- 4.31
- Other Operating Expenses Total
- 43.25
- Total Operating Expense
- 171.34
- Operating Income
- 31.47
- Net Income Before Taxes
- 28.1
- Net Income
- 20.86
- Diluted Normalized EPS
- 2.08
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 194.99
- Selling/ General/ Admin Expenses Total
- 29.6
- Depreciation/ Amortization
- 4.34
- Other Operating Expenses Total
- 42.55
- Total Operating Expense
- 165.11
- Operating Income
- 29.89
- Net Income Before Taxes
- 27.12
- Net Income
- 20.05
- Diluted Normalized EPS
- 2
- Period
- 2024-03-31
- Total Assets
- 1092.54
- Total Liabilities
- 559.98
- Total Equity
- 532.56
- Tangible Book Valueper Share Common Eq
- 52.55
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -7.46
- Cashfrom Investing Activities
- -102.39
- Cashfrom Financing Activities
- 82.38
- Net Changein Cash
- -27.46
- Period
- 2023-12-31
- Total Revenue
- 201.78
- Selling/ General/ Admin Expenses Total
- 30.6
- Depreciation/ Amortization
- 4.14
- Other Operating Expenses Total
- 39.38
- Total Operating Expense
- 169.46
- Operating Income
- 32.31
- Net Income Before Taxes
- 29.56
- Net Income
- 22.26
- Diluted Normalized EPS
- 2.23
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gufic Biosciences Technical
Moving Average
SMA
- 5 Day352.37
- 10 Day360.97
- 20 Day367.38
- 50 Day367.91
- 100 Day367.17
- 300 Day398.34
Gufic Biosciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 329
- 4.2
- 1.29
- 571.15
- 257.85
- 3678.62
- Orchid Pharma
- 708.95
- 5.65
- 0.8
- 1998
- 603.8
- 3599.82
- Gufic Biosciences
- 351
- -1.25
- -0.35
- 501.1
- 285
- 3519.75
- Morepen Laboratories
- 62.76
- 0.45
- 0.72
- 100.8
- 41.66
- 3438.96
- Alembic
- 115.3
- 0.9
- 0.79
- 169
- 85.55
- 2951.66
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 27.72
- 2.56
- 11
- 22.95
- Orchid Pharma
- 35.8
- 2.82
- 2.14
- 2.75
- Gufic Biosciences
- 50.6
- 5.87
- 22.25
- 10.48
- Morepen Laboratories
- 28.32
- 2.95
- 13.59
- 5.91
- Alembic
- 9.48
- 1.26
- 12.21
- 63.51
Gufic Biosciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results & Final Dividend
- 14-Feb-25
- Quarterly Results & Others
- 14-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results & ESOP
- 29-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Feb-25
- 07-Jan-25
- POM
- 25-Sept-24
- 04-Sept-24
- AGM
- 29-Sept-23
- 13-Sept-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-May-25
- -
- -
- 0.1
- 29-May-24
- -
- 18-Sept-24
- 0.1
- 29-May-23
- -
- 21-Sept-23
- 0.1
- 04-Jun-21
- -
- 09-Sept-21
- 0.1


